|
 
- 积分
- 3053
- 威望
- 3053
- 包包
- 5595
|
Glance at last issue:' ?# f+ W: y' X$ Y& Z' t# N- [6 v
" q, Y2 q* s4 o
"This enabled us to transplant as many as one billion of these cells per patient. The finding of improvement in ascites in a significant number of patients is impressive and somewhat surprising, suggesting that cell transplantation might be clinically significant beyond the improvement in laboratory parameters."--Dr. Mark A. Zern of the University of California Davis Medical Center.
0 k- n' a& B) t0 y& Z) s) K# x, X
"You have those who're against stem-cell research taking on extreme ideas like reproductive cloning, 'clone armies' and the idea that we're going to have half-humans and half-animal creatures developed. Then on the side of those who support stem-cell research — those who want to garner public policy support for the field — almost out of necessity, [they] are using hype in their presentations of the promise of stem-cell research...This exhibition isn't about taking sides in the stem-cell debate, it's about creating a place for reflection."--Tim Caulfield, research director of the Health Law Institute at the University of Alberta.4 m4 `' L2 r' G( a* G" b& v
+ q/ I+ Z3 ~ G* k- S) f4 z! `“Since genetic aberrations are often associated with cancers, it is vital that cell lines destined for clinical use are free from cancer-associated genomic alterations.”--senior author Jeanne F. Loring, PhD, professor and Director of the Center for Regenerative Medicine at The Scripps Research Institute.0 [: H! w) B5 E% A2 j
5 |& }8 t" u% N"Both types of human pluripotent cells, those derived from embryos and IPSCs had higher frequencies of genomic aberrations than other cell types...Most strikingly, we observed a higher frequency of genomic duplications in hESCs and deletions in iPSCs, when compared to non-pluripotent samples."--Louise Laurent, assistant professor in the UCSD Department of Reproductive Medicine.
9 ]2 F7 V( C; A% w) ]8 ^+ Q5 `' u: n" H( B
“Such findings are not really new, but it is good to see more studies addressing this obvious problem. It obviously matters because if these genetically abnormal cells are used as ‘therapies’ and injected into vulnerable and often desperate patients, the genetic mutations will cause and have caused serious immune rejection reactions in the patients. This means that not only will their diseases not be cured, but that they will be exacerbated by the introduction of cancer-causing agents.”--Bioethics expert Dr. Dianne Irving.
3 B9 e7 p: t9 E' ^$ r- i" j, Y/ {2 X) p- g
"The iPS cells produced through NuPotential's safer reprogramming processes are expected to offer us many advantages in drug discovery and drug rescue applications of our Human Clinical Trials in a Test Tube platform. We also expect these iPS cells to play a key role in our regenerative medicine initiatives focused on heart and liver disease and cartilage-repair. This initial NuPotential/VistaGen collaboration is a perfect next step to advance leading-edge stem cell technology at both companies."-- Shawn K. Singh, JD, VistaGen's Chief Executive Officer.
: M8 L1 x- T; d- ~
2 J+ ~! V8 a1 ^“My hope, is that, twenty years from now when stem cell transplants are commonplace, we’ll look back and say the first reduced-intensity transplant using bone marrow to treat a skin disease was done here at Columbia.”--Angela M. Christiano, the Richard & Mildred Rhodebeck Professor of Dermatology and Genetics & Development, vice chair for research in the Department of Dermatology, and the director of the Center for Human Genetics at CUMC.6 A3 d3 Y' _$ }1 f6 O
, V/ \7 _% x0 c* u- t“We are not at all in the top echelon of the state’s stem cell research facilities yet. But we hope to be there within two years.”--Glenn Monastersky, director of operations at Rensselaer’s Center for Biotechnology and Interdisciplinary Studies.
! E5 o1 e- Y$ ]! [- r9 [) E
( y* v$ I! u" ~"Our trial is not false hope, because these people have no hope to start with, and we intend to improve this. About 300 paralysed people have been done worldwide with their own stem cells and nobody has died. It is safe and some have gained more bodily functions."--Matamata resident Noela Vallis.
. _2 B5 C) v& X9 K1 ^5 L1 U& b9 |. B I+ r
“There are many companies developing microRNA-based drugs. Delivery of miRNAs is a challenge, but the field is moving fast through the preclinical stage.”--Dean Tang, Ph.D., professor in MD Anderson’s Department of Molecular Carcinogenesis.
$ L% w7 J [# t7 |& ^/ Y0 h2 S7 x( ~5 B4 I& W1 e+ A
“This is a high-profile area of research. When things succeed, they raise hopes among researchers, the public, and, of course, among investors. When they fall short, they also dramatically impact expectations across the board. The benefits can be incredible, but so are the risks, particularly when you get to the pivotal clinical trials stage.”--Robert J. Deans, svp, regenerative medicine, Athersys.
2 t, z$ W/ |2 p5 w0 H# G1 D. x! [6 h2 M5 I
“Public expectation is unrealistic, and when you throw in a high-profile death, we don’t want what happened to gene therapy to happen to stem cells. Jesse Gelsinger’s death caused the gene therapy field to take a major hit, from which it still hasn’t recovered. Stem cell research would do well to avoid such a tragedy. At the frontiers, the risks and the rewards are the biggest.”--David Magnus, Ph.D., director at Stanford Center of Biomedical Ethics and professor of medicine and biomedical ethics, pediatrics at Stanford University.
) r9 @5 d% M- E/ l/ f
3 y, [ E: a! `! h" x! t$ ^, s9 U) c! O- T
This issue:) r4 u7 _9 k/ U7 L, K
2 U n0 y I( t6 F5 @' e) d" D
) G2 i# s9 K2 Q* C# E2 S
: T4 Q5 z# |5 h* a
Video news:; {* f+ O6 n" C6 N% S4 K4 Q
Innovative Stem-Cell Surgery Helps Old Dogs Gain New Pep
) ~/ q! v+ e! w/ Y6 {/ ^% ?http://www.cbsatlanta.com/news/26529028/detail.html! c& t m# u) b& W# f2 o. }* w8 i) k9 e
+ E0 b8 _. X. }; ^9 F
Stem Cells For ALS: Medicine's Next Big Thing?- K& V5 B! x) X0 N9 {9 U
http://www.wftv.com/health/26526840/detail.html+ q( h/ p7 O7 F# N
+ g9 h' \, x- g: J' ?% hStem Cell Research Gets Huge Boost at UAMS2 l8 z. ^+ A( @& ]; v) L# S5 G$ V
http://arkansasmatters.com/news-fulltext?nxd_id=3856468 X1 p7 b9 t, o' q2 g9 Q+ Y
# G$ U8 j& R: P; @5 iScientists target arthritis with stem cells9 V# O$ _' V% F- J
http://video.au.msn.com/watch/vi ... -stem-cells/xfrmfh1( |- s9 V! c D; k' q6 o/ m
|
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 20
包包 + 30
查看全部评分
|
发表于 2011-1-24 21:51
